Xenon Pharmaceuticals Inc. (NASDAQ: XENE) experienced a dramatic selloff on Friday, with shares plunging more than 30% after the company announced a temporary halt in new patient enrollment across its psychiatry programs. The move came just days after the biotech firm submitted a New Drug Application (NDA) for its lead candidate, azetukalner, in focal-onset seizures.
The contrasting signals created significant uncertainty among investors, who ultimately focused on the safety concerns. Xenon's stock traded at $39.72 by 3:20 p.m. ET on September 18, down $17.63 (30.7%) from Thursday's close of $57.35. Trading volume surged to 14.8 million shares, roughly 24 times the average of the prior four sessions, according to Yahoo Finance data. The stock briefly touched $39.55, leaving it just 10% above its 52-week low of $35.97.
Psychiatry Program Pause
The company announced it had temporarily stopped enrolling new patients in studies evaluating azetukalner for major depressive disorder (MDD) and bipolar depression following a review of neuropsychiatric adverse events. Patients already enrolled in the randomized trials and their open-label extensions will continue, Xenon said.
Xenon described the events as consistent with the drug's known safety profile and mechanism, noting that such events were not observed in the earlier Phase 2 X-NOVA study. However, the company did not disclose the number of affected patients, the specific nature of the events, or potential dosing adjustments under consideration. This lack of detail complicates investor assessment of whether the issue is a manageable dosing problem or a fundamental limitation for the drug in psychiatry.
The ongoing Phase 2/3 X-NOVA2 trial has enrolled approximately 360 patients, about 80% of its original 450-patient target. Xenon believes this population is sufficient to detect a clinically meaningful change in the primary depression-score endpoint. Topline results are expected in the first quarter of 2027, which could provide clarity on efficacy before the expansion strategy is fully resolved.
Market Impact
The selloff appears to reflect a sharp reduction in the market's valuation of azetukalner's potential in depression and bipolar disorder, rather than a rejection of the epilepsy filing. Based on Xenon's June 30 share count of 96.75 million common shares plus 2.93 million pre-funded warrants, Friday's decline erased approximately $1.76 billion in equity value from the prior close. (This estimate uses a dated share count and is not a reported market-cap figure.)
Epilepsy Filing Progresses
Despite the psychiatry setback, the epilepsy program remains on track. Xenon confirmed that the pause does not affect its epilepsy trials, and the NDA for azetukalner in focal seizures is now under review by the U.S. Food and Drug Administration (FDA). In the pivotal X-TOLE2 study, the 25-milligram dose reduced monthly focal-seizure frequency by 53.2% from baseline versus 10.4% for placebo, while the 15-milligram dose produced a 34.5% reduction. Both comparisons were statistically significant, according to Xenon's March filing.
However, tolerability data from the epilepsy program showed notable trade-offs. Treatment-emergent adverse events led to discontinuation in 14.5% of patients at 25 milligrams, compared with 4.8% at 15 milligrams and 3.2% on placebo. Dizziness was the most common adverse event. Xenon reported more than 1,500 patient-years of exposure across the epilepsy program, and the ongoing X-TOLE3 and X-ACKT studies continue to enroll.
Financial Position
Xenon's balance sheet provides a cushion to address the safety questions. The company reported $1.245 billion in cash, equivalents, and marketable securities as of June 30, with an operating plan funded into 2029. Research and development spending was $99.2 million in the second quarter, and the net loss was $110.7 million. While this cash position reduces near-term financing pressure, it does not resolve the compound-level safety concerns.
Key Catalysts Ahead
Investors will now focus on three critical milestones: FDA acceptance of the focal-seizure NDA and the assigned review date, additional disclosures from Xenon about the psychiatric adverse events and any revised dosing strategies, and the X-NOVA2 readout expected in early 2027. Until the safety picture becomes clearer, the market is likely to value the epilepsy franchise separately, treating the psychiatry program as uncertain optionality rather than a reliable second growth driver.
